Form D · Biotechnology
Chinook Therapeutics U.S., Inc.
Seattle, WA · CIK 0001768185
Offering snapshot reported Oct 21, 2020 · SEC filing
- Reported sold
- $115M Offering amount: $115M
- Investors reported
- 25 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 17, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 21, 2020 | Initial | $115,000,000 | No comparison | 25 | SEC filing |
| Aug 29, 2019 | Initial | $65,000,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-378507
Source: Form D, filed Oct 21, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Srinivas Akkaraju | Director |
| Srini Akkaraju | Director |
| Jeremy Caldwell | Director |
| Jerel Davis | Director |
| Eric Dobmeier | Director, Executive |
| Paul Eisenberg | Director |
| Tom Frolich | Executive |
| Alan Glicklich | Executive |
| Sam Hall | Director |
| Andrew King | Executive |
| Preston Klassen | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1600 Fairview Ave. E. Suite 100
Seattle, WA, 98102
Seattle, WA, 98102